The author, veterinary anesthesiologist Shotaro Nagahama of Gifu University in Japan, proposes a working model in which general anesthesia and alpha2-agonists shift the apparent set-point of fluid homeostasis along a wet-to-dry axis. In the awake state, intake and excretion are tightly coupled: drink too much water and free-water clearance rises rapidly to defend osmolality and volume around a neutral operating point. Under anesthesia, that coupling weakens — and the entire curve relating filling state to urine output appears displaced toward conservation.

The mechanistic case for this wet-biased state is convergent. Anesthetic drugs reduce arterial pressure and cardiac output, pushing renal perfusion toward the limits of autoregulation and lowering glomerular filtration. But perfusion mechanics alone cannot explain the oliguria. In a randomized clinical study, sevoflurane anesthesia reduced urine output and sodium excretion while raising plasma renin compared with propofol, and population volume-kinetic analyses show that general anesthesia can strongly suppress the urinary excretion of infused crystalloid. The neuroendocrine milieu amplifies the effect: surgical stress and nociceptive input drive non-osmotic arginine vasopressin (AVP) secretion, peritoneal opening and visceral manipulation during abdominal surgery can further augment AVP release, and renal sympathetic nerve activity together with renin-angiotensin-aldosterone signaling promotes tubular sodium and water reabsorption.

Translational work adds a crucial autonomic layer. In a series spanning pediatric anesthesia and large-animal models, sevoflurane was associated with renal sodium and water retention, reduced renal blood flow, and increased renal sympathetic nerve activity. When the kidney was surgically denervated, excretory function normalized and renal blood flow improved during sevoflurane anesthesia — implicating renal sympathetic pathways as a key mediator of the retention-biased phenotype. From the set-point perspective, intraoperative oliguria is a physiologically plausible output of a regulated, conservation-biased state. The author is careful, however, to note that this interpretation is not clinically reassuring: the same low-output phenotype may coexist with impaired perfusion, insufficient effective circulating volume, or evolving kidney injury, so contextual assessment remains essential.

Alpha2-agonists appear to push the system in the opposite direction. Dexmedetomidine’s clinical pharmacology is dominated by central sympatholysis, and mechanistic studies show it inhibits hypothalamic paraventricular nucleus neurons involved in autonomic regulation and AVP-related pathways — providing a plausible central substrate for suppressing antidiuretic signaling. By reducing sympathetic outflow, including to the kidney, alpha2-agonists may also diminish renal sympathetic-driven tubular reabsorptive tone. The hemodynamic profile, with an early pressor phase followed by sympatholytic hypotension, can contribute transiently to pressure natriuresis, but the clinically salient pattern is often a sustained, dilute, high-output diuresis that is difficult to attribute to a one-off pressure effect alone.

Human evidence, though dominated by case reports and small series, is remarkably stereotyped: urine output rises abruptly to high volumes, urine becomes dilute, serum sodium may rise if replacement lags, and the phenotype resolves with dose reduction or discontinuation. Most reports exclude obvious osmotic drivers such as glucose or mannitol and do not suggest structural renal injury. Comparative veterinary physiology provides the most direct support, because controlled studies can measure urine indices and hormones systematically. In dogs, medetomidine produces dose-dependent increases in urine output with decreased urine osmolality and specific gravity, alongside decreases in plasma AVP at higher doses and increases in atrial natriuretic peptide. Alpha2-antagonists such as atipamezole and yohimbine can attenuate the diuresis and reverse the AVP-related changes, supporting receptor-mediated mechanisms rather than nonspecific nephrotoxicity. Similar diuresis occurs in cats, and rat studies using the peripherally restricted alpha2-antagonist vatinoxan suggest that peripheral alpha2-dependent processes may also contribute to the urinary phenotype.

The unified model has a distinctive feature: it does not assume a fixed urine-output curve on which patients merely move as volume changes. Instead, anesthesia and alpha2-agonists are proposed to shift the curve itself, so the same observed filling condition maps to different urine-output phenotypes. Operationally, movement along a curve would be inferred when transient changes in filling or fluid loading alter urine output without changing the underlying volume-diuresis relationship; a curve shift would be supported when the threshold or slope of that relationship differs between drug states under otherwise comparable hemodynamic, osmotic, and drug-exposure conditions. The author emphasizes that set-point is used operationally here — describing a testable shift in the relation between filling state and urine-output phenotype — not to imply that a new defended reference value has already been experimentally demonstrated.

One of the most striking predictions concerns breakthrough diuresis during ordinary anesthesia. Even in anesthetized preparations, diuresis and urine dilution can be gated by central volume or atrial-pressure signals linked to AVP suppression. Increasing left atrial pressure in anesthetized dogs provokes a reversible water diuresis with a fall in circulating AVP, and this response is abolished when AVP is clamped exogenously. Conversely, in anesthetized rats, acute volume expansion fails to elicit volume diuresis or natriuresis when right atrial pressure is prevented from rising — despite similar cardiac output and mean arterial pressure. This provides a mechanistic backbone for a key prediction: under a wet-biased anesthetic set-point, escalating fluid may remain clinically silent until central filling, venous or atrial pressure, or related neuroendocrine permissive signals cross a threshold, after which urine output rises nonlinearly. The same framework explains why some patients without overt hypovolemia become oliguric soon after induction, yet later begin producing urine as time under anesthesia and cumulative fluid administration increase — even when arterial pressure appears stable.

The model yields several falsifiable predictions. Greater alpha2-agonist exposure — through a higher loading dose, higher infusion rate, longer duration, or greater cumulative exposure — should increase the probability, earlier emergence, and persistence of dilute polyuria, while dose reduction or pharmacologic antagonism should shift the phenotype back toward lower output and greater concentration. If alpha2-associated polyuria reflects a dry-biased state, urine osmolality should fall before or during the rise in output, and serum sodium and osmolality should remain stable only if free-water losses are replaced adequately — otherwise they should increase progressively. Direct AVP or copeptin measurement would test whether the trajectory is accompanied by inappropriately low antidiuretic signaling relative to plasma tonicity. Definitive experiments should compare graded volume-diuresis curves across awake, anesthetized, and alpha2-exposed states while measuring arterial pressure, cardiac output, venous or atrial filling indices, AVP or copeptin, urine osmolality, sodium excretion, and serum sodium.

Clinically, the framework does not replace individualized goal-directed fluid therapy, which uses dynamic cardiovascular variables to guide fluid and vasoactive treatment. It addresses a different question: why urine output may decouple from those hemodynamic targets when renal excretion is governed by a shifted peri-anesthetic regulatory state. A low urine output is neither automatically benign nor automatically a marker of renal injury — in a wet-biased state it may reflect neuroendocrine conservation, while in other contexts it may signal hypoperfusion or evolving kidney injury. Escalating crystalloid purely to normalize urine output can contribute to fluid overload. Conversely, under a dry-biased set-point during alpha2-agonist infusion, the key hazard is progressive intravascular depletion if urinary losses are not matched — particularly when clinicians interpret high output as reassuring renal competence. If replacement lags, hypernatremia becomes a predictable risk. The author also situates the model within a familiar theme in anesthesia physiology: anesthetic drugs do not merely perturb measured variables, they shift thresholds and operating points that govern compensatory responses — as seen in thermoregulation, ventilatory control, and baroreflex function. The fluid set-point axis proposed here fits naturally into this broader idea: anesthesia as the management of drug-modifiable regulated states, rather than isolated numeric abnormalities to be corrected reflexively.

Subject of Research: Set-point shifts in peri-anesthetic fluid homeostasis: a conceptual framework informed by α2-agonist diuresis

Article Title: Set-point shifts in peri-anesthetic fluid homeostasis: a conceptual framework informed by α2-agonist diuresis

Article References: Nagahama, S. (2026). Set-point shifts in peri-anesthetic fluid homeostasis: a conceptual framework informed by α2-agonist diuresis. Frontiers in Anesthesiology, 5, Article 1873909. https://doi.org/10.3389/fanes.2026.1873909

Image Credits: AI Generated

DOI: 10.3389/fanes.2026.1873909

Keywords: anesthesia, dexmedetomidine, fluid homeostasis, oliguria, polyuria, vasopressin, set-point, perioperative medicine, shifts, peri-anesthetic, fluid, homeostasis